3RZ3

human cdc34 e2 in complex with cc0651 inhibitor

• Total interactions analyzed: 6
• Total true interactions: 3
• Strongest Interaction:
  • Chains: B-D
  • Int. Res.: 20
  • Norm. En. per Res.: -1.8266
• Hub Node: A(2)

All Interactions

Chains	Hydro. Bond Ener. (kJ/mol)	Elec. Ener. (kJ/mol)	VDW. Ener. (kJ/mol)	Tot. Stab. Ener. (kJ/mol)	#int. res.	# Short cont.	#Hydr. int.	#VDW pairs	#salt bridges	#Pot. fav. elec. int	#Pot. unfav. elec. int
A-B	-11.1157	7.6473	-65.4787	-68.9471	49	3	2	2605	0	4	8
A-C	-4.7024	-1.0555	-88.3916	-94.1494	52	3	0	4545	0	19	20
B-D	0.0	0.0	-36.5313	-36.5313	20	3	0	1470	0	1	1

Interface residues

• A-B: ALA140A, ALA140B, ARG113A, ARG76B, ASN135A, ASN135B, ASN141A, ASN141B, ASN85B, ASP143A, ASP143B, ASP91A, ASP91B, CYS93A, CYS93B, GLU112A, GLU88A, GLU88B, GLY90A, GLY90B, ILE94A, ILE94B, ILE96A, LEU97A, LEU97B, PHE137A, PHE137B, PRO139A, PRO139B, PRO84A, PRO84B, SER138A, SER138B, SER145A, SER145B, SER95A, SER95B, THR136A, THR136B, THR89A, THR89B, TYR87A, TYR87B, VAL142A, VAL142B, VAL146A, VAL146B, VAL92A, VAL92B
• A-C: ALA12C, ARG121C, ARG159A, ARG166A, ASN115C, ASN50A, ASP158A, ASP163A, GLN10C, GLN118C, GLU160A, GLU16C, GLU22C, GLU23C, GLU35C, GLU54A, GLY156A, GLY19C, GLY36C, GLY47A, GLY55A, GLY56A, ILE165A, LEU13C, LEU14C, LEU15C, LEU170A, LEU17C, LEU20C, LEU32C, LEU38C, LYS11C, LYS155A, LYS157A, LYS167A, LYS18C, PHE58A, PRO116C, PRO48A, PRO49A, PRO69C, SER154A, SER9C, THR117C, THR162A, THR51A, TRP114C, TRP151A, TYR52A, TYR53A, TYR68C, VAL169A
• B-D: ARG113B, ASN115B, ASN119D, ASP67B, ASP67D, GLN118B, GLU16D, LEU13D, LEU15D, PRO116B, PRO69B, PRO69D, PRO72B, SER71B, SER71D, THR117B, TRP114B, TYR68D, TYR70B, TYR70D